IBDEI14P ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18122,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,18123,0)
 ;;=I13.0^^88^910^8
 ;;^UTILITY(U,$J,358.3,18123,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18123,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,18123,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,18123,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,18124,0)
 ;;=I13.10^^88^910^10
 ;;^UTILITY(U,$J,358.3,18124,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18124,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,18124,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,18124,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,18125,0)
 ;;=I13.11^^88^910^11
 ;;^UTILITY(U,$J,358.3,18125,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18125,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,18125,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,18125,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,18126,0)
 ;;=I13.2^^88^910^9
 ;;^UTILITY(U,$J,358.3,18126,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18126,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,18126,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,18126,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,18127,0)
 ;;=I15.0^^88^910^15
 ;;^UTILITY(U,$J,358.3,18127,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18127,1,3,0)
 ;;=3^Renovascular Hypertension
 ;;^UTILITY(U,$J,358.3,18127,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,18127,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,18128,0)
 ;;=I15.1^^88^910^3
 ;;^UTILITY(U,$J,358.3,18128,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18128,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,18128,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,18128,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,18129,0)
 ;;=I15.2^^88^910^2
 ;;^UTILITY(U,$J,358.3,18129,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18129,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,18129,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,18129,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,18130,0)
 ;;=I15.8^^88^910^16
 ;;^UTILITY(U,$J,358.3,18130,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18130,1,3,0)
 ;;=3^Secondary Hypertension,Oth
 ;;^UTILITY(U,$J,358.3,18130,1,4,0)
 ;;=4^I15.8
 ;;^UTILITY(U,$J,358.3,18130,2)
 ;;=^5007074
 ;;^UTILITY(U,$J,358.3,18131,0)
 ;;=I15.9^^88^910^17
 ;;^UTILITY(U,$J,358.3,18131,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18131,1,3,0)
 ;;=3^Secondary Hypertension,Unspec
 ;;^UTILITY(U,$J,358.3,18131,1,4,0)
 ;;=4^I15.9
 ;;^UTILITY(U,$J,358.3,18131,2)
 ;;=^5007075
 ;;^UTILITY(U,$J,358.3,18132,0)
 ;;=I16.0^^88^910^14
 ;;^UTILITY(U,$J,358.3,18132,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18132,1,3,0)
 ;;=3^Hypertensive Urgency
 ;;^UTILITY(U,$J,358.3,18132,1,4,0)
 ;;=4^I16.0
 ;;^UTILITY(U,$J,358.3,18132,2)
 ;;=^8133013
 ;;^UTILITY(U,$J,358.3,18133,0)
 ;;=I16.1^^88^910^7
 ;;^UTILITY(U,$J,358.3,18133,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18133,1,3,0)
 ;;=3^Hypertensive Emergency
 ;;^UTILITY(U,$J,358.3,18133,1,4,0)
 ;;=4^I16.1
 ;;^UTILITY(U,$J,358.3,18133,2)
 ;;=^8204721
 ;;^UTILITY(U,$J,358.3,18134,0)
 ;;=I16.9^^88^910^6
 ;;^UTILITY(U,$J,358.3,18134,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18134,1,3,0)
 ;;=3^Hypertensive Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,18134,1,4,0)
 ;;=4^I16.9
 ;;^UTILITY(U,$J,358.3,18134,2)
 ;;=^5138600
